The Consumer Health Products Association will be holding its annual Regulatory, Scientific & Quality Conference virtually for the first time this year. The 2020 conference, slated for Sept. 1-3, will employ a dynamic virtual platform to showcase speakers from the Food and Drug Administration, the Federal Trade Commission, U.S. Pharmacopeia, academia and the industry — offering both live and on-demand content, with the latter including insights on CBD regulations.
CHPA said that it also would be offering networking opportunities and on-demand content in addition to the live program. This year’s program will focus on the impact that COVID-19 has had on the OTC industry, as well as major trends and emerging issues. There also will be a panel discussion the future of dietary supplements, as well as a session on medical device technology and regulation that will be available to attendees. Many on-demand panels will feature discussions of such topics as CBD regulation and the quality and safety of supplement products.
This year’s program includes:
- Lucinda Buhse, director of the FDA’s Office of Testing and Research, a division of the Center for Drug Evaluation and Research, who will discuss “Creating Value Through Quality Metrics” and metrics’ use as a tool for business growth in an interactive manner;
- Dr. Linda Katz, director of the FDA’s Office of Cosmetics and Colors at the Center for Food Safety & Applied Nutrition, whose session is called ‘Regulatory Perspective on Consumer Preferences and Perceptions” and will focus on consumer demand for natural, organic and botanical ingredients in products, as well as the accompanying regulatory issues;
- Amanda Pike-McCrudden, a social science analyst at the CDER’s various Divisions of Nonprescription Drug Products, who will discuss the role of behavioral sciences in shaping effective product communication in a session titled “Enabling Consumer Decision Making in the Self-Care Environment”; and
- Richard Cleland, assistant director of advertising practices at the FTC, who will participate in the “Staying Smart in a Smart World,” which will focus on the FTC’s role in oversight of emerging digital technologies.
The event also will include an FDA/USP Leadership Panel Discussion, a live discussion on “COVID-19 Impact on OTC Industry,” a panel called “OTC Technology and Emerging Policies,” and a panel on “Current Topics in Sustainability.”
On-demand topics and trends in nutrition and supplements will include:
- Dietary Supplement Use in the United States;
- Endocannabinoid System: Product Profiles and Outcomes We need to Know;
- HEMP/CBD Oils – Product Profiling and Market Launch Requirements;
- DSHEA: The First 25 Years, Now What?; and
- The Media: Information that Affects the Dietary Supplements Category.
Additional panels include:
- OTC Monograph Reform and Hot Topic
- Enabling Consumer Decision Making in the Self-Care Environment
- Alternatives to Animal Testing
- Customer Complaints: Best Practices from Case Studies
A version of this article originally appeared in Drug Store News.